ANAB vs. YMAB, IRON, SLN, PAHC, NUVB, EOLS, ARCT, SVRA, PHAR, and DNTH
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Y-mAbs Therapeutics (YMAB), Disc Medicine (IRON), Silence Therapeutics (SLN), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), Evolus (EOLS), Arcturus Therapeutics (ARCT), Savara (SVRA), Pharming Group (PHAR), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical preparations" industry.
AnaptysBio (NASDAQ:ANAB) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
AnaptysBio received 232 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 65.54% of users gave AnaptysBio an outperform vote while only 60.51% of users gave Y-mAbs Therapeutics an outperform vote.
70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 35.5% of AnaptysBio shares are owned by insiders. Comparatively, 21.5% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Y-mAbs Therapeutics has a net margin of -25.26% compared to AnaptysBio's net margin of -953.66%. Y-mAbs Therapeutics' return on equity of -20.72% beat AnaptysBio's return on equity.
AnaptysBio has a beta of -0.32, suggesting that its share price is 132% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
AnaptysBio presently has a consensus target price of $46.22, suggesting a potential upside of 77.64%. Y-mAbs Therapeutics has a consensus target price of $16.57, suggesting a potential downside of 2.18%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe AnaptysBio is more favorable than Y-mAbs Therapeutics.
In the previous week, AnaptysBio had 2 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 5 mentions for AnaptysBio and 3 mentions for Y-mAbs Therapeutics. AnaptysBio's average media sentiment score of 0.81 beat Y-mAbs Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.
Y-mAbs Therapeutics has higher revenue and earnings than AnaptysBio. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Summary
AnaptysBio beats Y-mAbs Therapeutics on 10 of the 18 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
